Analyst Upgrades

• BMO Capital upgraded Concho (CXO) to outperform from market perform and has a $73 price target on the stock. The firm cites valuation and sustainable growth for the upgrade.
• Sterne Agee upgraded City Holding (CHCO) to buy from neutral based on valuation. The firm has a $34 target on the stock.
• UBS upgraded Werner Enterprises (WERN) to neutral from sell based on valuation. The firm raised its price target to $21.50 from $21.
• Nvidia (NVDA) was upgraded to equal weight from underweight at Morgan Stanley.
• Colfax (CFX) was upgraded to neutral from underperform at BofA/Merrill.
• Camden Property (CPT) was upgraded to top pick from outperform at RBC Capital.

Biotechs are fascinating. They have such great promise, yet very few of them actually turn those promises into money. Cures for all types of cancers always seem imminent with promising (there's that word again) results from mice or small control groups. Phase I testing is completed and all kinds of good stuff seems possible. Then something usually happens. Usually not very good things.

Most of the time, it's discovered that what works in mice doesn't work in men (or women). Or that the group was too small for meaningful data and when a larger group is studied, the efficacy isn't there. Or as soon as there's a bounce in the stock price, much more stock is issued and dilution occurs.